基础胰岛素，可实现每周给药一次，极大减少了注射频率，提高了患者依从性。同时具有良好的安全性和有效性，是糖尿病领域的革新重磅产品。
Once weekly basal insulin, which dramatically reduces injection frequency and improves patient compliance. It has demonstrated an excellent safety and efficacy profile, positioning it as a promising innovative blockbuster in the diabetes treatment market.
